195 related articles for article (PubMed ID: 11485619)
1. Selective increases in HIV-specific neutralizing antibody and partial reconstitution of cellular immune responses during prolonged, successful drug therapy of HIV infection.
Kim JH; Mascola JR; Ratto-Kim S; VanCott TC; Loomis-Price L; Cox JH; Michael NL; Jagodzinski L; Hawkes C; Mayers D; Gilliam BL; Birx DC; Robb ML
AIDS Res Hum Retroviruses; 2001 Jul; 17(11):1021-34. PubMed ID: 11485619
[TBL] [Abstract][Full Text] [Related]
2. Longitudinal study of humoral immune responses in HIV type 1 subtype CRF01_AE (E)-infected Thai patients with different rates of disease progression.
Chuenchitra T; Wasi C; Louisirirojchanakul S; Nitayaphan S; Sutthent R; Cox JH; De Souza MS; Brown AE; Birx DL; Polonis VR
AIDS Res Hum Retroviruses; 2003 Apr; 19(4):293-305. PubMed ID: 12804005
[TBL] [Abstract][Full Text] [Related]
3. Role of hepatitis C virus (HCV) viremia and HCV genotype in the immune recovery from highly active antiretroviral therapy in a cohort of antiretroviral-naive HIV-infected individuals.
Antonucci G; Girardi E; Cozzi-Lepri A; Capobianchi MR; De Luca A; Puoti M; Petrelli E; Carnevale G; Rizzardini G; Grossi PA; Viganò P; Moioli MC; Carletti F; Solmone M; Ippolito G; Monforte AD; ;
Clin Infect Dis; 2005 Jun; 40(12):e101-9. PubMed ID: 15909251
[TBL] [Abstract][Full Text] [Related]
4. Association of HIV neutralizing antibody with lower viral load after treatment interruption in a prospective trial (A5170).
McLinden RJ; Paris RM; Polonis VR; Close NC; Su Z; Shikuma CM; Margolis DM; Kim JH
AIDS; 2012 Jan; 26(1):1-9. PubMed ID: 21971356
[TBL] [Abstract][Full Text] [Related]
5. The effect of highly active antiretroviral therapy on binding and neutralizing antibody responses to human immunodeficiency virus type 1 infection.
Binley JM; Trkola A; Ketas T; Schiller D; Clas B; Little S; Richman D; Hurley A; Markowitz M; Moore JP
J Infect Dis; 2000 Sep; 182(3):945-9. PubMed ID: 10950795
[TBL] [Abstract][Full Text] [Related]
6. Characterization of the HIV-1 specific humoral immune response during highly active antiretroviral therapy (HAART).
Morris MK; Katzenstein DA; Israelski D; Zolopa A; Hendry RM; Hanson CV
J Acquir Immune Defic Syndr; 2001 Dec; 28(5):405-15. PubMed ID: 11744827
[TBL] [Abstract][Full Text] [Related]
7. The effect of HAART on humoral immune response in primary HIV-1 infected patients.
Pastori C; Barassi C; Lillo F; Longhi R; Capiluppi B; Nozza S; Galli A; Uberti-Foppa C; Lazzarin A; Tambussi G; Lopalco L
J Biol Regul Homeost Agents; 2002; 16(1):9-17. PubMed ID: 12003182
[TBL] [Abstract][Full Text] [Related]
8. Reconstitution of spontaneous neutralizing antibody response against autologous human immunodeficiency virus during highly active antiretroviral therapy.
Kimura T; Yoshimura K; Nishihara K; Maeda Y; Matsumi S; Koito A; Matsushita S
J Infect Dis; 2002 Jan; 185(1):53-60. PubMed ID: 11756981
[TBL] [Abstract][Full Text] [Related]
9. Neutralizing antibodies against autologous human immunodeficiency virus Type 1 isolates in patients with increasing CD4 cell counts despite incomplete virus suppression during antiretroviral treatment.
Sarmati L; d'Ettorre G; Nicastri E; Ercoli L; Uccella I; Massetti P; Parisi SG; Vullo V; Andreoni M
Clin Diagn Lab Immunol; 2001 Jul; 8(4):822-4. PubMed ID: 11427434
[TBL] [Abstract][Full Text] [Related]
10. Potent antiretroviral therapy initiates normalization of hypergammaglobulinemia and a decline in HIV type 1-specific antibody responses.
Notermans DW; de Jong JJ; Goudsmit J; Bakker M; Roos MT; Nijholt L; Cremers J; Hellings JA; Danner SA; de Ronde A
AIDS Res Hum Retroviruses; 2001 Jul; 17(11):1003-8. PubMed ID: 11485617
[TBL] [Abstract][Full Text] [Related]
11. Decrease of replicative capacity of HIV isolates after genotypic guided change of therapy.
Sarmati L; Nicastri E; Montano M; Dori L; Buonomini AR; d'Ettorre G; Gatti F; Parisi SG; Vullo V; Andreoni M
J Med Virol; 2004 Apr; 72(4):511-6. PubMed ID: 14981751
[TBL] [Abstract][Full Text] [Related]
12. Neutralizing antibodies do not mediate suppression of human immunodeficiency virus type 1 in elite suppressors or selection of plasma virus variants in patients on highly active antiretroviral therapy.
Bailey JR; Lassen KG; Yang HC; Quinn TC; Ray SC; Blankson JN; Siliciano RF
J Virol; 2006 May; 80(10):4758-70. PubMed ID: 16641269
[TBL] [Abstract][Full Text] [Related]
13. Functional T cell reconstitution and human immunodeficiency virus-1-specific cell-mediated immunity during highly active antiretroviral therapy.
Pontesilli O; Kerkhof-Garde S; Notermans DW; Foudraine NA; Roos MT; Klein MR; Danner SA; Lange JM; Miedema F
J Infect Dis; 1999 Jul; 180(1):76-86. PubMed ID: 10353864
[TBL] [Abstract][Full Text] [Related]
14. Effect of combination antiretroviral therapy on human immunodeficiency virus 1 specific antibody responses in subtype-C infected children.
Kumar S; Batra H; Singh S; Chawla H; Singh R; Katpara S; Hussain AW; Das BK; Lodha R; Kabra SK; Luthra K
J Gen Virol; 2020 Dec; 101(12):1289-1299. PubMed ID: 32915123
[TBL] [Abstract][Full Text] [Related]
15. Correlates of antiviral immune restoration in acute and chronic HIV type 1 infection: sustained viral suppression and normalization of T cell subsets.
Dyer WB; Kuipers H; Coolen MW; Geczy AF; Forrester J; Workman C; Sullivan JS
AIDS Res Hum Retroviruses; 2002 Sep; 18(14):999-1010. PubMed ID: 12396452
[TBL] [Abstract][Full Text] [Related]
16. HIV-1-infected children on HAART: immunologic features of three different levels of viral suppression.
Zaccarelli-Filho CA; Ono E; Machado DM; Brunialti M; Succi RC; Salomão R; Kallás EG; de Moraes-Pinto MI
Cytometry B Clin Cytom; 2007 Jan; 72(1):14-21. PubMed ID: 17041945
[TBL] [Abstract][Full Text] [Related]
17. Epstein-Barr virus and human immunodeficiency virus serological responses and viral burdens in HIV-infected patients treated with HAART.
O'Sullivan CE; Peng R; Cole KS; Montelaro RC; Sturgeon T; Jenson HB; Ling PD
J Med Virol; 2002 Jul; 67(3):320-6. PubMed ID: 12116021
[TBL] [Abstract][Full Text] [Related]
18. Autologous neutralizing antibody to human immunodeficiency virus-1 and replication-competent virus recovered from CD4+ T-cell reservoirs in pediatric HIV-1-infected patients on HAART.
Ching N; Nielsen-Saines KA; Deville JG; Wei LS; Garratty E; Bryson YJ
AIDS Res Hum Retroviruses; 2010 May; 26(5):585-91. PubMed ID: 20455762
[TBL] [Abstract][Full Text] [Related]
19. Residual viraemia in HIV-1-infected patients with plasma viral load Ostrowski SR; Katzenstein TL; Pedersen BK; Gerstoft J; Ullum H
Scand J Immunol; 2008 Dec; 68(6):652-60. PubMed ID: 19055701
[TBL] [Abstract][Full Text] [Related]
20. Evidence of immune reconstitution in antiretroviral drug-experienced patients with advanced HIV disease.
Landay AL; Bettendorf D; Chan E; Spritzler J; Schmitz JL; Bucy RP; Gonzalez CJ; Schnizlein-Bick CT; Evans T; Squires KE; Phair JP
AIDS Res Hum Retroviruses; 2002 Jan; 18(2):95-102. PubMed ID: 11839142
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
